Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Flipping the idea

Initial attempts to develop bryostatin 1 have been disappointing for cancer researchers because of myalgia, a dose-limiting toxicity. But the protein kinase C modulator may have applications in other indications, in particular Alzheimer's disease (AD), according to a report in last week's Proceedings of the National Academy of Sciences.

"Bryostatin 1 turns out to be the most potent PKC activator ever described," said Daniel Alkon,

Read the full 658 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers